"rationale","versionIdentifier","id","uuid:ID","instanceType"
"The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","2","StudyVersion_1","5363f329-26dd-46d3-9e30-38f5bc276921","StudyVersion"
